[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336862-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336862-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","investigating-ppt2s-role-in-ovarian-cancer-prognosis-and-immunotherapy-outcomes","Investigating PPT2’s role in ovarian cancer prognosis and immunotherapy outcomes","","Ovarian cancer remains the leading cause of death among gynecological malignancies, and dependable molecular biomarkers for prognosis are still lacking. This study examines whether PPT2 expression relates to survival, immune infiltration, and underlying mechanisms in ovarian cancer. RNA-seq and clinical data from TCGA, GTEx, and GEO were analyzed using Kaplan–Meier, Cox regression, nomograms, and calibration, while GSEA identified linked pathways. PPT2 overexpression and multi-level validation showed decreased PPT2 associates with poorer outcomes and predicts potential immunotherapy benefit.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/investigating-ppt2s-role-in-ovarian-cancer-prognosis-and-immunotherapy-outcomes/336862/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/investigating-ppt2s-role-in-ovarian-cancer-prognosis-and-immunotherapy-outcomes/336862.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of this study on PPT2 in ovarian cancer?","Question",{"text":63,"@type":64},"To determine how PPT2 expression is associated with ovarian cancer prognosis, immune infiltration, and potential molecular mechanisms.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which datasets and analyses were used to evaluate PPT2’s prognostic value?",{"text":68,"@type":64},"RNA-seq and clinical data were obtained from TCGA, GTEx, and GEO, followed by Kaplan–Meier analysis, univariate and multivariate Cox regression, nomogram, and calibration.",{"name":70,"@type":61,"acceptedAnswer":71},"How does PPT2 expression relate to immune infiltration and immunotherapy outcomes?",{"text":72,"@type":64},"PPT2 shows a negative correlation with immune infiltration and immune/stromal/estimate scores, and patients with low PPT2 expression may benefit more from immunotherapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336862,1790859117,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Xu etal. Journal of Ovarian Research (2024) 17:198 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-024-01527-9](https://doi.org/10.1186/s13048-024-01527-9)  \nRESEARCH Open Access  \nInvestigating PPT2’s role in ovarian cancer prognosis and immunotherapy outcomes  \nHui Xu 1, Yan Zhang 1, Zhen Xie 1, Xiao-feng Xie 1, Wen-lan Qiao 1, Miao Wang 1, Bei-bei Zhao 1 and Tian Hua 1*  \nAbstract  \nOvarian cancer (OC) remains the primary cause of mortality among gynecological malignancies, and the identification of reliable molecular biomarkers to prognosticate OC outcomes is yet to be achieved. The genepalmitoyl protein thioesterase 2 (PPT2), which has been sparsely studied in OC, was closely associated with metabolism. This study aimed to determine the association between PPT2 expression, prognosis, immune infiltration, and potential molecular mechanisms in OC. We obtained the RNA-seq and clinical data from The Cancer Genome Atlas (TCGA), The Genotype-Tissue Expression (GTEx) and Gene Expression Omnibus (GEO) databases, then Kaplan-Meier analysis, univariate Cox regression, multivariate Cox regression, nomogram, and calibration were conducted to assess and verify the role of PPT2 . Gene set enrichment analysis (GSEA) was used to figure out the closely correlated pathways with PPT2 . Overexpression experiment was performed to explore the function of PPT2 . Our findings showed that PPT2 mRNA expression was apparent down-regulation in OC tissue compared to normal ovarian tissues in TCGA, GTEx datasets, and GEO datasets. This differential expression was also confirmed in our in-house datasets at both the mRNA and protein levels. Decreased PPT2 expression correlated with lower survival rates in TCGA, several GEO datasets, and our in-house datasets. Multivariate analysis revealed that PPT2 was an independent factor in predicting better outcomes for OC patients in TCGA and GEO. A negative correlation was revealed between immune infiltration and PPT2 expression through Single-sample GSEA (ssGSEA) . Additionally, PPT2 was negatively correlated with an up-regulated immune score, stromal score, and estimate score, suggesting that patients with low PPT2 expression might benefit more from immunotherapy. Numerous chemical agents showed lower IC50 in patients with high PPT2 expression. In single-cell RNA sequencing (scRNA-seq) analysis of several OC datasets, we found PPT2 was mainly expressed in endothelial cells. Furthermore, we found that PPT2 inhibited OC cell proliferation in vitro. Our results demonstrated that PPT2 was considered a favorable prognostic biomarker for OC and may be vital in predicting response to immunotherapy and chemotherapy. Further research was needed to fully understand the relationship between PPT2 and immunotherapy efficacy in OC patients. Keywords PPT2, Ovarian cancer, Prognosis, Immunotherapy response, Tumor microenvironment  \n*Correspondence:  \nTian Hua  \n[huatian1982@163.com](huatian1982@163.com)  \n1Department of Gynecology, Affiliated Xingtai People Hospital of Hebei Medical University, 16 Hongxing Road, Xingtai, Hebei 054001, China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, yo","cbCailCUY7UvxVFu","https://ap.wps.com/l/cbCailCUY7UvxVFu","pdf",10421628,17,"English","# Abstract\n## Introduction","[{\"question\":\"What is the purpose of this study on PPT2 in ovarian cancer?\",\"answer\":\"To determine how PPT2 expression is associated with ovarian cancer prognosis, immune infiltration, and potential molecular mechanisms.\"},{\"question\":\"Which datasets and analyses were used to evaluate PPT2’s prognostic value?\",\"answer\":\"RNA-seq and clinical data were obtained from TCGA, GTEx, and GEO, followed by Kaplan–Meier analysis, univariate and multivariate Cox regression, nomogram, and calibration.\"},{\"question\":\"How does PPT2 expression relate to immune infiltration and immunotherapy outcomes?\",\"answer\":\"PPT2 shows a negative correlation with immune infiltration and immune/stromal/estimate scores, and patients with low PPT2 expression may benefit more from immunotherapy.\"}]","Investigating PPT2’s role in ovarian cancer prognosis and immunotherapy outcomes | PDF",1790016901,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50de109deae699d419315c745b3630dc.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5dbddefa5386784fdbfdd1dd4b9e9604.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c0ce9b20122a6a242556b6f8bc35e46.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/397bde70797f2df12a1b1c2e6b118d0a.webp",980,1306]